Skip header and navigation
Did you mean name:"Pekka mäntyselkä"? Also try mäntyselkä.

Refine By

7 records – page 1 of 1.

Concomitant use of analgesics and psychotropics in home-dwelling elderly people-Kuopio 75 + study.

https://arctichealth.org/en/permalink/ahliterature173209
Source
Br J Clin Pharmacol. 2005 Sep;60(3):306-10
Publication Type
Article
Date
Sep-2005
Author
Sirpa Hartikainen
Pekka Mäntyselkä
Kirsti Louhivuori-Laako
Hannes Enlund
Raimo Sulkava
Author Affiliation
Division of Geriatrics, Department of Public Health and General Practice, University of Kuopio, Kuopio, Finland. Sirpa.Hartikainen@uku.fi
Source
Br J Clin Pharmacol. 2005 Sep;60(3):306-10
Date
Sep-2005
Language
English
Publication Type
Article
Keywords
Age Factors
Aged
Aged, 80 and over
Analgesics - therapeutic use
Cross-Sectional Studies
Female
Finland
Homebound Persons
Humans
Male
Pain - drug therapy
Psychotropic Drugs - therapeutic use
Abstract
To investigate the extent of concomitant use of analgesic and psychotropic medicines among home-dwelling elderly people aged at least 75 years in Finland.
This was a population-based study in Finland, performed as part of Kuopio 75 + study focusing on the clinical epidemiology of diseases, medication and functional capacity. A random sample of 700 persons was drawn from the total population of the city of Kuopio, eastern Finland, aged 75 years on January 1, 1998 (n = 4518). Ninety-nine persons could not be examined and 78 were living in long-term institutions, so that the number of home-dwelling elderly persons amounted to 523. A trained nurse interviewed the participants about their use of medicines, and a geriatrician examined their overall physical and mental status. Dementia and depression were diagnosed according to the DSM IV criteria. Both regular and irregular prescribed and nonprescribed drug use was recorded.
Every fourth elderly person (27.2%) used analgesics and psychotropics concomitantly, this use becoming twice as common with advancing age (19.6% in the age group 75-79 years, 38.2% among the oldest, aged 85 + years). Concomitant use of psychotropics and opioids also became more common with increasing age (2.8% in age group 75-79 years and 9.6% in the oldest group, aged 85 + years). The use of opioids was nearly twice as common among concomitant users (19.7%) than among those using only analgesics (11.3%). Concomitant users suffered from interfering daily pain and daily pain at rest more commonly than nonusers of analgesics. Depression, sleeping problems and polypharmacy were more common among the concomitant users, who had also had more hip fractures than the rest.
Concomitant use of analgesics and psychotropics becomes more common with advancing age and is a potential risk factor for adverse drug effects.
Notes
Cites: Int J Geriatr Psychiatry. 2002 Sep;17(9):874-8312221663
Cites: J Korean Med Sci. 2002 Feb;17(1):65-7011850591
Cites: J Am Geriatr Soc. 2002 Nov;50(11):1861-512410908
Cites: Ageing Res Rev. 2003 Jan;2(1):57-9312437996
Cites: Epidemiology. 2003 Mar;14(2):240-612606892
Cites: Drugs. 2003;63(6):525-3412656651
Cites: Int Clin Psychopharmacol. 2003 May;18(3):163-712702896
Cites: Int J Geriatr Psychiatry. 2003 Dec;18(12):1135-4114677146
Cites: Eur J Clin Pharmacol. 2004 Jan;59(11):849-5014652704
Cites: J Psychiatr Res. 1975 Nov;12(3):189-981202204
Cites: J Gerontol. 1992 Jul;47(4):M111-51624693
Cites: Med J Aust. 1993 Mar 15;158(6):414-78479356
Cites: Lancet. 1998 May 2;351(9112):1303-79643791
Cites: Am J Epidemiol. 1998 Nov 1;148(9):887-929801019
Cites: Br J Clin Pharmacol. 1998 Dec;46(6):531-39862240
Cites: Ann Pharmacother. 2005 Jan;39(1):11-615598966
Cites: Am J Epidemiol. 2000 Mar 1;151(5):488-9610707917
Cites: J Am Geriatr Soc. 2000 Sep;48(9):1073-910983906
Cites: Drugs Aging. 2001;18(1):45-6111232738
Cites: Med Care. 2001 May;39(5):425-3511317091
Cites: Ann Intern Med. 2001 Oct 16;135(8 Pt 2):731-511601956
Cites: J Clin Epidemiol. 2001 Nov;54(11):1181-611675171
Cites: Arch Intern Med. 2001 Dec 10-24;161(22):2721-411732938
Cites: Pain. 2002 Jan;95(1-2):75-8211790469
Cites: J Clin Psychiatry. 2002 Sep;63(9):817-2512363124
PubMed ID
16120070 View in PubMed
Less detail

Do people regard cheaper medicines effective? Population survey on public opinion of generic substitution in Finland.

https://arctichealth.org/en/permalink/ahliterature137726
Source
Pharmacoepidemiol Drug Saf. 2011 Feb;20(2):185-91
Publication Type
Article
Date
Feb-2011
Author
Reeta Heikkilä
Pekka Mäntyselkä
Riitta Ahonen
Author Affiliation
Faculty of Health Sciences, School of Pharmacy, Social Pharmacy, University of Eastern Finland, Kuopio, Finland. reeta.heikkila@uef.fi
Source
Pharmacoepidemiol Drug Saf. 2011 Feb;20(2):185-91
Date
Feb-2011
Language
English
Publication Type
Article
Keywords
Adolescent
Adult
Age Factors
Aged
Aged, 80 and over
Chi-Square Distribution
Consumer Product Safety
Cost Savings
Drug Costs
Drug Substitution - adverse effects - economics - psychology
Drugs, Generic - adverse effects - economics - therapeutic use
Female
Finland
Health Care Surveys
Health Knowledge, Attitudes, Practice
Humans
Insurance, Pharmaceutical Services
Logistic Models
Male
Middle Aged
National Health Programs
Odds Ratio
Patient satisfaction
Public Opinion
Questionnaires
Risk assessment
Sex Factors
Time Factors
Treatment Refusal
Young Adult
Abstract
Generic substitution (GS) is an important way to decrease medical costs. We aimed to study the opinions and attitudes of Finnish people about GS five years after it was introduced, the reasons for substituting and what people think about generic medicines.
We sent a postal survey to a random stratified population sample of 3000 Finnish people aged at least 18 years in 2008. The random sample was drawn from five mainland counties. The sampling was conducted by the Finnish Population Register Centre. The response rate was 62% (n=1844) after exclusion of unobtainable addressees (n=34).
Most of the respondents (70.9%) considered GS a good law reform. However, there were many respondents who were unsure about their opinion (26.9%). The respondents also held the opinion that cheaper medicines are effective (80.9%) and that GS does not cause any risk to drug safety (84.9%). Most of the respondents (88.4%) who had substituted their medicines had not noticed any difference between the previously used and substituted medicines. Two main reasons for substituting were a desire to save money and recommendation by pharmacists. Of the respondents, 16.3% had experience with both substituting and refusing it. The percentage of the respondents who only had experience with refusing GS was 8.6%. Female gender, older age and use of prescription drugs were associated with refusing.
Finnish people consider GS a good reform. They also have confidence in the effect of cheaper medicines. Savings are the main reason for accepting GS.
PubMed ID
21254290 View in PubMed
Less detail

Erythropoietin, ferritin, haptoglobin, hemoglobin and transferrin receptor in metabolic syndrome: a case control study.

https://arctichealth.org/en/permalink/ahliterature120324
Source
Cardiovasc Diabetol. 2012;11:116
Publication Type
Article
Date
2012
Author
Päivi Hämäläinen
Juha Saltevo
Hannu Kautiainen
Pekka Mäntyselkä
Mauno Vanhala
Author Affiliation
Department of Internal Medicine, Tampere University Hospital, Teiskontie, Tampere, Finland. Paivi.O.Hamalainen@uta.fi
Source
Cardiovasc Diabetol. 2012;11:116
Date
2012
Language
English
Publication Type
Article
Keywords
Biological Markers - blood
Case-Control Studies
Chi-Square Distribution
Cross-Sectional Studies
Dyslipidemias - blood - ethnology
Erythropoietin - blood
European Continental Ancestry Group
Female
Ferritins - blood
Finland - epidemiology
Glucose Metabolism Disorders - blood - ethnology
Haptoglobins - analysis
Hemoglobins - analysis
Humans
Hypertension - blood - ethnology
Male
Metabolic Syndrome X - blood - ethnology
Middle Aged
Obesity, Abdominal - blood - ethnology
Receptors, Transferrin - blood
Up-Regulation
Abstract
Increased ferritin concentrations are associated with metabolic syndrome (MetS). The association between ferritin as well as hemoglobin level and individual MetS components is unclear. Erythropoietin levels in subjects with MetS have not been determined previously. The aim of this study was to compare serum erythropoietin, ferritin, haptoglobin, hemoglobin, and transferrin receptor (sTFR) levels between subjects with and without MetS and subjects with individual MetS components.
A population based cross-sectional study of 766 Caucasian, middle-aged subjects (341 men and 425 women) from five age groups born in Pieksämäki, Finland who were invited to a health check-up in 2004 with no exclusion criteria. Laboratory analyzes of blood samples collected in 2004 were done during year 2010. MetS was defined by National Cholesterol Education Program criteria.
159 (53%) men and 170 (40%) women of study population met MetS criteria. Hemoglobin and ferritin levels as well as erythropoietin and haptoglobin levels were higher in subjects with MetS (p?
Notes
Cites: Diabetes Care. 2000 Dec;23(12):1835-911128362
Cites: Eur J Heart Fail. 2010 Apr;12(4):354-920335353
Cites: JAMA. 2004 Feb 11;291(6):711-714871914
Cites: J Clin Endocrinol Metab. 2004 Jun;89(6):2678-8315181041
Cites: Blood. 1990 May 1;75(9):1870-62331526
Cites: Physiol Rev. 1992 Apr;72(2):449-891557429
Cites: J Appl Physiol (1985). 1995 Oct;79(4):1278-858567573
Cites: J Atheroscler Thromb. 2010 Apr 30;17(4):369-7720103974
Cites: Obesity (Silver Spring). 2010 Jul;18(7):1449-5619816411
Cites: Cardiovasc Diabetol. 2010;9:8821156040
Cites: Cardiovasc Diabetol. 2010;9:9221167068
Cites: Blood. 2011 Apr 28;117(17):4425-3321346250
Cites: Clin Chim Acta. 2012 Mar 22;413(5-6):636-4122212623
Cites: Cardiovasc Diabetol. 2012;11:2522417460
Cites: PLoS One. 2012;7(7):e4091922815867
Cites: Am J Epidemiol. 2012 Aug 1;176(3):253-6022791741
Cites: Am J Kidney Dis. 1997 Oct;30(4):532-419328369
Cites: N Engl J Med. 1999 Feb 11;340(6):448-549971870
Cites: Diabetes Care. 2005 Aug;28(8):2061-316043762
Cites: Diabetes. 2005 Aug;54(8):2277-8616046292
Cites: Gastroenterology. 2006 Sep;131(3):788-9616952548
Cites: Nature. 2006 Dec 14;444(7121):881-717167477
Cites: Am J Epidemiol. 2007 May 1;165(9):1047-5417284722
Cites: Trans R Soc Trop Med Hyg. 2008 Aug;102(8):735-4218486167
Cites: Int J Obes (Lond). 2008 Nov;32(11):1665-918779821
Cites: J Clin Endocrinol Metab. 2008 Dec;93(12):4690-618796516
Cites: Diabetes. 2009 Jan;58(1):95-10318984735
Cites: Diabetes. 2009 Mar;58(3):718-2519074987
Cites: Atherosclerosis. 2009 Apr;203(2):626-3218845301
Cites: Circulation. 2009 Oct 20;120(16):1640-519805654
Cites: Proc Nutr Soc. 2009 Nov;68(4):370-719698203
Cites: J Clin Invest. 2002 Oct;110(7):1037-4412370282
PubMed ID
23016887 View in PubMed
Less detail

Glycemic control and health-related quality of life among older home-dwelling primary care patients with diabetes.

https://arctichealth.org/en/permalink/ahliterature293508
Source
Prim Care Diabetes. 2017 Dec; 11(6):577-582
Publication Type
Journal Article
Date
Dec-2017
Author
Anna-Kaisa Aro
Merja Karjalainen
Miia Tiihonen
Hannu Kautiainen
Juha Saltevo
Maija Haanpää
Pekka Mäntyselkä
Author Affiliation
Institute of Public Health and Clinical Nutrition, General Practice, University of Eastern Finland, Finland; Rantakylä Health Center, Siunsote, Finland. Electronic address: koistine@student.uef.fi.
Source
Prim Care Diabetes. 2017 Dec; 11(6):577-582
Date
Dec-2017
Language
English
Publication Type
Journal Article
Keywords
Activities of Daily Living
Age Factors
Aged
Aged, 80 and over
Aging
Biomarkers - blood
Blood Glucose - metabolism
Cognition
Cross-Sectional Studies
Diabetes Mellitus - blood - diagnosis - psychology - therapy
Female
Finland
Geriatric Assessment
Glycated Hemoglobin A - metabolism
Humans
Independent living
Male
Mental health
Mental Status and Dementia Tests
Mobility Limitation
Predictive value of tests
Primary Health Care
Quality of Life
Risk factors
Self Care - methods
Time Factors
Treatment Outcome
Abstract
To evaluate the health-related quality of life (HRQoL) and functional capacity in relation to glycemic control among older home-dwelling primary care patients.
Electronic patient records were used to identify 527 people over 65 years with diabetes. Of these, 259 randomly selected subjects were invited to a health examination and 172 of them attended and provided complete data. The participants were divided into three groups based on the HbA1c: good (HbA1c57mmol/mol (N=29)) glycemic control. HRQoL was measured with the EuroQol EQ-5D questionnaire. Functional and cognitive capacity and mental well-being were assessed with the Lawton Instrumental Activities of Daily Living (IADL) scale, Mini-Mental State Examination (MMSE) and Geriatric Depression Scale (GDS-15).
EQ-5D scores for good, intermediate and poor glycemic control were 0.78; 0.74 and 0.70, p=0.037. Sub-items of mobility (p=0.002) and self-care were the most affected (p=0.031). Corresponding trend was found for IADL, p=0.008. A significant correlation was found between MMSE scores and HbA1c.
Older primary care home-dwelling patients with diabetes and poorer glycemic control have lower functional capacity and HRQoL, especially in regard to mobility and self-care.
PubMed ID
28754430 View in PubMed
Less detail

Serum anti-inflammatory markers in general population subjects with elevated depressive symptoms.

https://arctichealth.org/en/permalink/ahliterature141201
Source
Neurosci Lett. 2010 Nov 5;484(3):201-5
Publication Type
Article
Date
Nov-5-2010
Author
Soili M Lehto
Leo Niskanen
Juhani Miettola
Tommi Tolmunen
Heimo Viinamäki
Pekka Mäntyselkä
Author Affiliation
Department of Psychiatry, Kuopio University Hospital, 70210 Kuopio, Finland. Soili.Lehto@kuh.fi
Source
Neurosci Lett. 2010 Nov 5;484(3):201-5
Date
Nov-5-2010
Language
English
Publication Type
Article
Keywords
Biological Markers - blood
Cohort Studies
Depressive Disorder - blood - diagnosis - pathology
Female
Finland
Humans
Inflammation Mediators - blood
Interleukin 1 Receptor Antagonist Protein - blood - physiology - secretion
Interleukin-10 - blood
Interleukin-6 - blood - physiology
Male
Middle Aged
Abstract
Anti-inflammatory substances have previously been suggested to show compensatory elevations in depressed individuals with pronounced inflammatory changes. In order to further clarify these observations, we examined depression-related alterations in the serum levels of anti-inflammatory markers interleukin (IL)-1 receptor antagonist (RA) and IL-10 and the pro-inflammatory marker IL-6 in 416 general population participants. Depression was evaluated with the Beck Depression Inventory (BDI). Participants with elevated depressive symptoms (BDI>14, n=44) had increased levels of IL-1 RA and IL-6. No changes were observed in their IL-10 levels. In multivariate modeling with adjustments for age, gender, obesity, regular smoking, alcohol use, metabolic syndrome, physical exercise, sleep disturbance, and the use of non-steroidal anti-inflammatory drugs, a high level of IL-1 RA was associated with an increased likelihood of belonging to the group with elevated depressive symptoms (OR for each 1 SD increase in the serum level of IL-1 RA: 2.17, 95% CI 1.35-3.48, p=0.001). The significance of IL-6 alterations did not persist in the same model. The pronounced secretion of anti-inflammatory marker IL-1 RA may reflect the presence of compensatory mechanisms during a depression-related inflammatory state.
PubMed ID
20800651 View in PubMed
Less detail

Serum omega-6 polyunsaturated fatty acids and the metabolic syndrome: a longitudinal population-based cohort study.

https://arctichealth.org/en/permalink/ahliterature122650
Source
Am J Epidemiol. 2012 Aug 1;176(3):253-60
Publication Type
Article
Date
Aug-1-2012
Author
Mauno Vanhala
Juha Saltevo
Pasi Soininen
Hannu Kautiainen
Antti J Kangas
Mika Ala-Korpela
Pekka Mäntyselkä
Author Affiliation
Unit of General Practice, Central Finland Central Hospital, Jyväskylä, Finland. mauno.vanhala@ksshp.fi
Source
Am J Epidemiol. 2012 Aug 1;176(3):253-60
Date
Aug-1-2012
Language
English
Publication Type
Article
Keywords
Age Factors
Body mass index
Chi-Square Distribution
Cholesterol, HDL - blood
Dietary Fats, Unsaturated - adverse effects - blood
Fatty Acids, Omega-3 - adverse effects - blood
Fatty Acids, Omega-6 - adverse effects - blood
Female
Finland - epidemiology
Humans
Longitudinal Studies
Magnetic Resonance Spectroscopy
Male
Metabolic Syndrome X - epidemiology - etiology
Middle Aged
Sex Factors
Abstract
The serum fatty acid composition reflects the dietary fatty acid composition from the past few days to several weeks. However, the role of serum omega-3 (from fish and fish oils) and omega-6 (from vegetable oils) polyunsaturated fatty acids (PUFAs) in the course of metabolic syndrome is poorly understood. At the Primary Health Care Unit in Pieksämäki, Finland, all subjects born in 1942, 1947, 1952, 1957, and 1962 (n = 1,294) were invited for health checkups in 1997-1998 and 2003-2004. Metabolic syndrome was defined by using the new, harmonized criteria. The serum omega-3 PUFAs, omega-6 PUFAs, and total fatty acids were analyzed by proton nuclear magnetic resonance spectroscopy. Altogether, data from both checkups were available for 665 subjects. After adjustment for age, sex, and baseline body mass index, the incidence of metabolic syndrome between the 2 checkups with a 6.4-year follow-up was inversely associated (P
PubMed ID
22791741 View in PubMed
Less detail

Weight change and lipoprotein particle concentration and particle size: a cohort study with 6.5-year follow-up.

https://arctichealth.org/en/permalink/ahliterature123839
Source
Atherosclerosis. 2012 Jul;223(1):239-43
Publication Type
Article
Date
Jul-2012
Author
Pekka Mäntyselkä
Hannu Kautiainen
Juha Saltevo
Peter Würtz
Pasi Soininen
Antti J Kangas
Mika Ala-Korpela
Mauno Vanhala
Author Affiliation
Institute of Public Health and Clinical Nutrition, Primary Health Care, School of Medicine, University of Eastern Finland, Kuopio, Finland. pekka.mantyselka@uef.fi
Source
Atherosclerosis. 2012 Jul;223(1):239-43
Date
Jul-2012
Language
English
Publication Type
Article
Keywords
Adult
Analysis of Variance
Biological Markers - blood
Cardiovascular Diseases - blood - epidemiology
Female
Finland - epidemiology
Humans
Linear Models
Lipoproteins - blood
Lipoproteins, HDL - blood
Lipoproteins, LDL - blood
Lipoproteins, VLDL - blood
Longitudinal Studies
Magnetic Resonance Spectroscopy
Male
Middle Aged
Obesity - blood - epidemiology - physiopathology
Overweight - blood - epidemiology - physiopathology
Particle Size
Risk assessment
Risk factors
Time Factors
Weight Gain
Weight Loss
Abstract
Obesity and overweight are related to unfavourable lipoprotein subclass profiles. Here we studied the relation between weight change and lipoprotein particle concentrations and sizes in a general population cohort in a longitudinal setting.
The cohort included 683 adults with a 6.5-year follow-up. Lipoprotein particle subclasses and mean particle sizes of VLDL, LDL, and HDL were measured by nuclear magnetic resonance spectroscopy.
During the follow-up period, a weight loss of at least 5% was associated with decreased particle concentrations of all apoB-containing subclasses and increased concentrations of large HDL particles. Coherently, weight gain (=5%) was associated with increases in all apoB-containing subclasses and decreases in total and medium HDL particle concentrations. The relatively largest increase occurred for large HDL particle concentration (24.1%, 95% CI 15.8-32.5) in weight loss and for large VLDL particle concentration (33.0%, 19.6-46.4) in weight gain. Weight change correlated positively with changes in apoB-containing lipoprotein particle concentrations and also with the change in average VLDL particle size. Negative correlations were found between weight change and the change in average LDL (r = -0.10) and HDL (r = -0.32) particle size, but not between weight change and total HDL particle concentration.
Moderate weight loss is related to favourable and weight gain to unfavourable changes in lipoprotein subclass profiles. These population level findings underline the importance of weight control as a modifier of cardiovascular risk factors.
PubMed ID
22658258 View in PubMed
Less detail

7 records – page 1 of 1.